AN2 Therapeutics, Inc. financial data

Symbol
ANTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1800 El Camino Real, Suite D, Menlo Park, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 875 % -58.8%
Debt-to-equity 10.8 % -3.21%
Return On Equity -54.2 % +9.1%
Return On Assets -48.9 % +8.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.1M shares +1.1%
Common Stock, Shares, Outstanding 29.9M shares +0.6%
Entity Public Float 41.1M USD -62.2%
Weighted Average Number of Shares Outstanding, Basic 29.8M shares +26.4%
Weighted Average Number of Shares Outstanding, Diluted 29.8M shares +26.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 40.5M USD -26.2%
General and Administrative Expense 14.1M USD -4.73%
Operating Income (Loss) -56.8M USD +18.4%
Net Income (Loss) Attributable to Parent -51.3M USD +20.7%
Earnings Per Share, Basic -1.72 USD/shares +37.2%
Earnings Per Share, Diluted -1.72 USD/shares +37.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.4M USD +36.5%
Cash, Cash Equivalents, and Short-term Investments 95.3M USD -16%
Assets, Current 86.3M USD -21.9%
Other Assets, Noncurrent 804K USD -22.9%
Assets 92.1M USD -33.6%
Accounts Payable, Current 3.32M USD +24%
Employee-related Liabilities, Current 1.68M USD -58.3%
Accrued Liabilities, Current 4.45M USD -33.3%
Liabilities, Current 10M USD -32.5%
Liabilities 10.2M USD -27.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 31K USD -88.7%
Retained Earnings (Accumulated Deficit) -206M USD -33.2%
Stockholders' Equity Attributable to Parent 81.8M USD -34.4%
Liabilities and Equity 92.1M USD -33.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.6M USD -51.7%
Net Cash Provided by (Used in) Financing Activities 349K USD +75.4%
Net Cash Provided by (Used in) Investing Activities 26.3M USD +141%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 29.9M shares +0.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.05M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 21.4M USD +36.5%
Deferred Tax Assets, Valuation Allowance 58.1M USD +39%
Deferred Tax Assets, Gross 58.1M USD +39%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -51.6M USD +19.5%
Operating Lease, Liability, Current 13K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 28.7M USD +38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.08M USD +42.6%
Additional Paid in Capital 288M USD +3.12%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 8.34M USD -0.88%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%